• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Can 1% Lidocaine Reduce Pain During IUD Insertion in Nulliparous Women?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • There is no standard of care for pain management for nulliparous women undergoing IUD insertion
  • Mody et al. (Obstetrics & Gynecology, 2018) assessed whether lidocaine paracervical block reduces pain during intrauterine device (IUD) placement

METHODS:

  • Randomized single-blinded (to participants) placebo-controlled trial (RCT)
  • Participants
    • Women receiving an IUD for contraception or abnormal bleeding
    • Ages 18-45
  • Women received either
    • 20-mL buffered 1% lidocaine paracervical block
      • 8 mL of 1% lidocaine buffered with 2 mL 8.4% sodium bicarbonate
      • 2 mL: Tenaculum at 12 o’clock
      • 18 mL: Vaginal fornices equally at 4 and 8 o’clock
    • No block
  • Blinding achieved using the following language
    • “You may or may not feel something”
    • Saline control not used because distention from saline can provide relief and not a true placebo
  • Primary outcome
    • Pain with IUD placement measured on a 100-mm visual analog scale
  • Secondary outcomes included
    • Pain with speculum placement, paracervical block administration and tenaculum placement at 5 minutes post procedure
    • Overall pain perception
  • Statistics
    • Sample size had 80% power to detect a 20-mm difference in visual analog scale scores (α=0.05)

RESULTS:

  • 64 women were enrolled and analyzed
    • 33 in the paracervical block arm | 31 in the no-block arm
  • Women who received the paracervical block reported less pain with IUD placement (P=.002)
    • Paracervical block: 33 mm
    • No block: 54 mm
  • Pain was significantly less in the block group for
    • Uterine sounding (30 mm vs 47 mm, P=.005)
    • 5 minutes after placement (12 mm vs 27 mm, P=.005)
    • Overall pain perception (30 mm vs 51 mm, P=.015)
  • Participants who received the paracervical block experienced more pain (P=.003) with block administration
    • Paracervical block: 30 mm
    • No block: 8 mm
  • There was no perceived pain difference for speculum insertion or tenaculum placement
  • In the no block group, women reported more often that IUD pain was worse than expected
    • Paracervical block: 1.6%
    • No block: 14.1%
  • In the paracervical group vs no block, women more often reported
    • No pain (10.9% vs 1.6%)
    • Pain not as bad as expected (29.7% vs 18.8%)

CONCLUSION:

    • 1% lidocaine (20mL) administered prior to IUD insertion lead to overall lower perceived pain
    • This study also provides valuable counseling information for those who opt for the lidocaine block

…the patient may be informed during counseling that the paracervical block typically does cause some pain (30 mm on a 100-mm scale), but that the paracervical block reduces pain with IUD placement, pain 5 minutes after the procedure, and perceived pain for the overall procedure.

Learn More – Primary Sources:

Paracervical Block for Intrauterine Device Placement Among Nulliparous Women: A Randomized Controlled Trial.

image_pdfFavoriteLoadingFavorite

< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

ACOG & SMFM Guidance on the Use of IUDs and Contraceptive Implants
IUDs and Implants: How to Manage Potential LARC Complications
Outcomes after Immediate Postpartum IUD Insertion

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site